Last $410.10 USD
Change Today +1.16 / 0.28%
Volume 863.8K
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
Mexico
As of 8:10 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

225 Binney Street

Cambridge, MA 02142

United States

Phone: 617-679-2000

Fax:

Biogen Idec Inc., a biotechnology company, focuses on discovering, developing, manufacturing, and marketing therapies for the treatment of neurological, autoimmune, and hematologic disorders. Marketed Products The company’s principal marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis (MS); ALPROLIX for hemophilia B; and ELOCTATE for hemophilia A. MS Products The company develops, manufactures, and markets various products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. AVONEX (interferon beta-1a), an intramuscular injectable therapy, indicated for the treatment of patients with relapsing forms of MS. AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. The principal markets for AVONEX are the U.S., the United Kingdom, France, Germany, Italy, and Spain. PLEGRIDY (peginterferon beta-1a), a subcutaneous injectable therapy, indicated in the U.S. for the treatment of patients with relapsing forms of MS and in the European Union (E.U.) for relapsing-remitting MS (RRMS). PLEGRIDY received approval from the European Commission (EC) in 2014 and the U.S. Food and Drug Administration (FDA) in 2014. TECFIDERA (dimethyl fumarate), an oral therapy indicated in the U.S. for the treatment of patients with relapsing forms of MS and in the EU for people with RRMS. TECFIDERA was approved by the FDA in 2013 and the EC in 2014. TYSABRI (natalizumab), a monoclonal antibody approved in various countries as a monotherapy for the treatment of patients with relapsing forms of MS. TYSABRI is also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. The principal markets for TYSABRI in MS are the U.S., the United Kingdom, France, Germany, Italy and Spain. TYSABRI was approved in Japan in 2014. FAMPYRA (prolonged-release fampridine tablets), is indicated for the improvement of walking ability in adult patients with MS. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The company has a license from Acorda Therapeutics, Inc. (Acorda) to develop and commercialize FAMPYRA in all markets outside the U.S. Its principal markets for FAMPRYA are France, Germany, Spain, and Canada. Hemophilia Products The company develops, manufactures and markets products designed to treat patients with hemophilia A and B. Hemophilia A is caused by having substantially reduced or no Factor VIII activity and hemophilia B is caused by having substantially reduced or no Factor IX activity, each of which is needed for normal blood clotting. ALPROLIX (Coagulation Factor IX (Recombinant), Fc Fusion Protein), a recombinant DNA-derived, coagulation Factor IX concentrate indicated in the U.S. for treatment in adults and children with hemophilia B for control and prevention of bleeding episodes, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ALPROLIX was approved by the FDA in 2014 and in Japan in 2014. ELOCTATE (Antihemophilic Factor (Recombinant), Fc Fusion Protein), a recombinant DNA-derived, antihemophilic factor indicated in the U.S. for treatment in adults and children with hemophilia A for control and prevention of bleeding episodes, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ELOCTATE was approved by the FDA in 2014 and in Japan in 2014. The company collaborateswith Swedish Orphan Biovitrum AB (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. Collaboration The company collaborates with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, on the development and commercialization of RITUXAN. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. RITUXAN (rituximab), a prescribed monoclonal

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $410.10 USD +1.16

BIIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.61 USD +0.21
Astellas Pharma Inc ¥1,923 JPY +24.50
AstraZeneca PLC 4,465 GBp -36.50
Bristol-Myers Squibb Co $61.46 USD +0.24
Novo Nordisk A/S kr316.00 DKK +4.30
View Industry Companies
 

Industry Analysis

BIIB

Industry Average

Valuation BIIB Industry Range
Price/Earnings 33.0x
Price/Sales 9.9x
Price/Book 8.9x
Price/Cash Flow 28.4x
TEV/Sales 9.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.